Mendus AB (publ) – ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel

Stockholm, Sweden

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announces that updated clinical data from the ALISON clinical trial with its lead product vididencel in ovarian cancer will be presented at the ESMO Gynaecological Cancers Annual Congress, being held from June 20-22, 2024 in Florence, Italy. The trial reached its primary objective of inducing tumor-directed immune responses in at least 10 patients treated with vididencel.

Ovarian cancer is the deadliest gynaecological cancer, mainly due to its high recurrence rate. Improving disease free and overall survival in advanced high grade serous ovarian carcinoma (HGSC) after primary treatment remains challenging. The Phase 1 ALISON trial explores the potential of vididencel to induce clinically relevant immune responses in ovarian cancer. The trial is fully enrolled (17 participants) and all participants have completed the vididencel treatment phase per April 2024. Vididencel-induced immune responses against tumor antigens that are regularly upregulated in HGSC were observed in 10 out of 15 patients evaluated so far, with 3 patients not reaching a vaccine induced response (VIR) due to high baseline responses. Vididencel treatment only gave mild adverse reactions, predominantly at the site of injection. The observed immune responses following vididencel treatment may provide the basis for an effective anti-tumor response. At week 22, 10 patients had stable disease and 7 patients had imaging-confirmed recurrence. To further evaluate clinical benefit, long-term follow-up of patients is ongoing.

Mendus anticipates to report the primary read-out of the ALISON trial based on immune response evaluation of all treated patients in 2024Q4.

Please see below for abstract details:

Abstract Number:  50P (poster presentation)

Abstract Title: Vididencel, a cell-based cancer vaccine, induces tumor-directed immune responses in high-grade serous ovarian carcinoma patients

Authors: A. Vledder, H. van Zeeburg, K. Brummel, A.L. Eerkens, N. van Rooij, A. Plat, J. Rovers, M. de Bruyn, H. Nijman

Session Date & Time: Thursday, 20 June 2024 between 12:30 – 13:30 CEST

After presentation, the poster will be made available on the Mendus website.

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

Links